Compare Microsoft (MSFT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Neurocrine Biosciences Inc — how do they compare? Microsoft trades at $492.82 (market cap $3.67T), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Microsoft is far larger — about 232.7× Neurocrine Biosciences Inc's market cap, and Microsoft pays a 0.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MSFT | NBIX | |
|---|---|---|
Market Cap | $3.67T | $15.77B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $185.50 |
52-Week Low | $352.83 | $123.10 |
Enterprise Value | $3.65T | $15.78B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $493.95, down 1.15% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding expectations of $4.24. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31% and a high ROE of 34.04%. News highlights AI leadership and Azure momentum, though capital expenditure concerns persist.
Outlook remains positive with an 80.49% analyst buy rating and a consensus price target of $560.43, implying significant upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 27.52, and macroeconomic volatility. The stock's strength in cloud computing and consistent profitability underpins long-term growth potential.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
